Ozanimod (Zeposia) for the subsequent treatment of relapsing multiple sclerosis with a high level of disease activity
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether ozanimod (trade name: Zeposia) has any advantages or disadvantages compared to interferon beta-1a for the treatment of active relapsing-remitting multiple sclerosis (RRMS) in people who have frequent relapses despite treatment.
For this assessment, the manufacturer provided two studies involving a total of 207 people. 116 of these participants had treatment with interferon beta-1a, and 91 of them were given ozanimod. The following results were found after one year: